mitoxantrone has been researched along with Menopause in 17 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer." | 9.07 | A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. ( Ashley, S; Jodrell, DI; Mansi, JL; McKinna, JA; Pearson, MC; Sinnett, HD; Smith, IE; Walsh, G, 1991) |
| "Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval." | 9.05 | Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984) |
| "Mitoxantrone (Novantrone; dihydroxyanthracenedione) is an anthraquinone previously shown to be active in human breast cancer." | 9.05 | A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. ( Allegra, JC; Bryan, S; Dukart, G; Henderson, IC; Reisman, A; Woodcock, T; Woolf, S, 1985) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 9.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "Improved prognosis in women with multiple sclerosis (MS) undergoing immunosuppressive treatment with mitoxantrone (MITO) has led to an increased interest in the effect of such treatments on fertility." | 7.74 | Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. ( Amato, MP; Capra, R; Cocco, E; Gallo, P; Marrosu, MG; Sardu, C; Trojano, M; Uccelli, A, 2008) |
| "A phase II trial in postmenopausal women with advanced breast cancer naive to cytotoxic treatment for recurrent disease was performed with a combinated chemo-endocrine regimen of prednimustine, methotrexate, mitoxantrone, 5-fluorouracil, and tamoxifen." | 7.67 | Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial. ( Andersson, M; Mouridsen, HT, 1988) |
| "A phase II study with mitoxantrone has been carried out in 30 metastatic breast cancer patients." | 7.67 | A phase II study of mitoxantrone in advanced breast cancer. ( Ardizzoni, A; Conte, PF; Gulisano, M; Lionetto, R; Pronzato, P; Repetto, L; Rosso, R; Scornavacche, V; Sertoli, MR, 1986) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "Congestive heart failure has been observed in one patient (doxorubicin)." | 6.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer." | 5.07 | A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. ( Ashley, S; Jodrell, DI; Mansi, JL; McKinna, JA; Pearson, MC; Sinnett, HD; Smith, IE; Walsh, G, 1991) |
| "Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval." | 5.05 | Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984) |
| "Mitoxantrone (Novantrone; dihydroxyanthracenedione) is an anthraquinone previously shown to be active in human breast cancer." | 5.05 | A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. ( Allegra, JC; Bryan, S; Dukart, G; Henderson, IC; Reisman, A; Woodcock, T; Woolf, S, 1985) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 5.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "Improved prognosis in women with multiple sclerosis (MS) undergoing immunosuppressive treatment with mitoxantrone (MITO) has led to an increased interest in the effect of such treatments on fertility." | 3.74 | Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. ( Amato, MP; Capra, R; Cocco, E; Gallo, P; Marrosu, MG; Sardu, C; Trojano, M; Uccelli, A, 2008) |
| "A phase II trial in postmenopausal women with advanced breast cancer naive to cytotoxic treatment for recurrent disease was performed with a combinated chemo-endocrine regimen of prednimustine, methotrexate, mitoxantrone, 5-fluorouracil, and tamoxifen." | 3.67 | Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial. ( Andersson, M; Mouridsen, HT, 1988) |
| "A phase II study with mitoxantrone has been carried out in 30 metastatic breast cancer patients." | 3.67 | A phase II study of mitoxantrone in advanced breast cancer. ( Ardizzoni, A; Conte, PF; Gulisano, M; Lionetto, R; Pronzato, P; Repetto, L; Rosso, R; Scornavacche, V; Sertoli, MR, 1986) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "Congestive heart failure has been observed in one patient (doxorubicin)." | 2.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| " Chronic administration of this compound is associated with the development of dose-dependent cardiotoxicity." | 1.27 | [Cytostatic therapy in metastatic breast cancer]. ( Lenzhofer, R; Rainer, H, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (76.47) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cocco, E | 1 |
| Sardu, C | 1 |
| Gallo, P | 1 |
| Capra, R | 1 |
| Amato, MP | 1 |
| Trojano, M | 1 |
| Uccelli, A | 1 |
| Marrosu, MG | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengeçti, S | 1 |
| Berkarda, B | 1 |
| Holmes, FA | 1 |
| Yap, HY | 1 |
| Esparza, L | 1 |
| Buzdar, AU | 1 |
| Hortobagyi, GN | 1 |
| Blumenschein, GR | 1 |
| Rainer, H | 1 |
| Lenzhofer, R | 1 |
| Makris, A | 1 |
| Powles, TJ | 1 |
| Dowsett, M | 1 |
| Osborne, CK | 2 |
| Trott, PA | 1 |
| Fernando, IN | 1 |
| Ashley, SE | 1 |
| Ormerod, MG | 1 |
| Titley, JC | 1 |
| Gregory, RK | 1 |
| Allred, DC | 1 |
| Stein, M | 1 |
| Borovik, R | 1 |
| Robinson, E | 1 |
| Jodrell, DI | 1 |
| Smith, IE | 1 |
| Mansi, JL | 1 |
| Pearson, MC | 1 |
| Walsh, G | 1 |
| Ashley, S | 1 |
| Sinnett, HD | 1 |
| McKinna, JA | 1 |
| Shenkenberg, TD | 1 |
| Von Hoff, DD | 2 |
| Andersson, M | 2 |
| Mouridsen, HT | 2 |
| Pronzato, P | 1 |
| Ardizzoni, A | 1 |
| Conte, PF | 1 |
| Gulisano, M | 1 |
| Lionetto, R | 1 |
| Repetto, L | 1 |
| Scornavacche, V | 1 |
| Sertoli, MR | 1 |
| Rosso, R | 1 |
| Cowan, JD | 1 |
| Neidhart, JA | 1 |
| Constanzi, JJ | 1 |
| Vaughn, CB | 1 |
| Allegra, JC | 1 |
| Woodcock, T | 1 |
| Woolf, S | 1 |
| Henderson, IC | 1 |
| Bryan, S | 1 |
| Reisman, A | 1 |
| Dukart, G | 1 |
| Bennett, JM | 1 |
| Byrne, P | 1 |
| Desai, A | 1 |
| White, C | 1 |
| DeConti, R | 1 |
| Vogel, C | 1 |
| Krementz, E | 1 |
| Muggia, F | 1 |
| Doroshow, J | 1 |
| Plotkin, D | 1 |
| Perren, TJ | 1 |
| Blackledge, G | 1 |
| Mould, JJ | 1 |
| Chetiyawardana, AD | 1 |
| Morrison, M | 1 |
| Hancock, A | 1 |
| Pedersen, L | 1 |
| Metz, R | 1 |
| Delgado, M | 1 |
| Keiling, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Prevot, G | 1 |
| Misset, JL | 1 |
| Grimbert, J | 1 |
| Mathe, G | 1 |
| Periti, P | 1 |
| della Cuna, GR | 1 |
| Pannuti, F | 1 |
| Mazzei, T | 1 |
| Preti, P | 1 |
| Martoni, A | 1 |
| Mini, E | 1 |
6 trials available for mitoxantrone and Menopause
| Article | Year |
|---|---|
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1984 |
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 1997 |
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1991 |
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica | 1985 |
A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Cardiac Output; Clinical Trial | 1985 |
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1985 |
11 other studies available for mitoxantrone and Menopause
| Article | Year |
|---|---|
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.
Topics: Adult; Amenorrhea; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Infertility, Female; | 2008 |
Mitoxantrone-cyclophosphamide-fluorouracil-combination chemotherapy in metastatic breast cancer. 3-Year-follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1989 |
[Cytostatic therapy in metastatic breast cancer].
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1984 |
Mitoxantrone as second-line single agent in metastatic breast cancer.
Topics: Breast Neoplasms; Female; Heart; Heart Function Tests; Humans; Infusions, Intravenous; Menopause; Mi | 1991 |
Possible mitoxantrone-induced amenorrhea.
Topics: Adult; Amenorrhea; Anthraquinones; Carcinoma, Adenoid Cystic; Estradiol; Female; Follicle Stimulatin | 1986 |
Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Fluoroura | 1988 |
A phase II study of mitoxantrone in advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Breast Neoplasms; Drug Evaluation; Female; Humans; Menopause; Middle Ag | 1986 |
Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1985 |
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1986 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1985 |